CSL Behring

CSL Behring is a biopharmaceutical company, manufacturing plasma-derived and recombinant therapeutic products and providing them to people in more than 100 countries. Its line of therapies includes products for the treatment of bleeding disorders such as hemophilia and von Willebrand Disease; primary immune deficiencies (PIDD); hereditary angioedema; inherited respiratory disease; and neurological disorders in certain markets. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in the newborn.[1]

CSL Behring LLC
IndustryBiopharmaceutical, health care
HeadquartersKing of Prussia, Pennsylvania
Key people
Paul Perreault, CEO and Managing Director of CSL Limited
Number of employees
27,000+[1]
Websitewww.cslbehring.com

CSL Behring operates CSL Plasma, one of the world's largest plasma collection networks, with more than 270 plasma collection centers in the U.S., Europe and China.[2]

CSL Behring's parent company, CSL Limited (ASX:CSL;USOTC:CSLLY), is headquartered in Melbourne, Victoria, Australia. As part of a global alignment, the CSL Behring brand was established in 2007. Previously known as ZLB Behring, the company's history dates back to 1904, when it was founded in Germany by Emil von Behring, the Nobel Prize-winning inventor of serum therapy or serology.[3]

History

CSL Behring is a combination of Behringwerke, founded in 1904 in Marburg, Germany by Emil von Behring, winner of the first Nobel prize in medicine; and the Commonwealth Serum Laboratories (CSL), established in Australia in 1916 to provide vaccines to the people of Australia.

Over the past century, CSL Behring has grown into one of the leading international biotechnology companies, acquiring along the way: Aventis Behring, U.S. plasma collector Nabi, which helped form the world's largest plasma collection network in CSL Plasma; Calimmune, a leader in gene-modification and cell-delivery technology; and Vitaeris, a biopharmaceutical company focused on the development of clazakizumab as a potential treatment option for organ transplant recipients experiencing rejection. The combined histories make CSL the innovative global leader it is today.

Products
Immunology
Coagulation/bleeding disorders
Pulmonary
  • Zemaira, freeze-dried Human Alpha1-proteinase inhibitor (A1-PI)
Critical care
  • AlbuRx, Alburex, Human Albumin Behring, Albuminar, human albumin solution (5%, 20% or 25% human albumin solutions)
  • Berinert P, freeze-dried human C1-esterase inhibitor (C1-INH) concentrate
  • Beriplex P/N, Kcentra, freeze-dried human prothrombin complex concentrate
  • Haemocomplettan P, RiaSTAP, freeze-dried human fibrinogen (factor I) concentrate
  • Kybernin P, freeze-dried human antithrombin III concentrate
  • Streptase, freeze-dried streptokinase
Wound healing

(Note: Product availability varies from country to country, depending on registration status.)[4]

Offices

The company is headquartered in King of Prussia, Pennsylvania.[5] It has 26,000+ employees in 30 countries.[1] Major manufacturing centers are located in Bern, Switzerland, Marburg, Germany, Kankakee, Illinois, and Broadmeadows, Australia.[5]

References
  1. http://cslbehring.com/about
  2. "Archived copy". Archived from the original on 2010-07-05. Retrieved 2011-02-04.CS1 maint: archived copy as title (link)
  3. http://nobelprize.org/nobel_prizes/medicine/laureates/1901/behring-bio.html
  4. "Archived copy" (PDF). Archived from the original (PDF) on 2010-11-20. Retrieved 2011-02-04.CS1 maint: archived copy as title (link)
  5. http://cslbehring.com/about/worldwide-locations.htm
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.